XKRX
253840
Market cap39mUSD
Jul 10, Last price
3,815.00KRW
1D
5.39%
1Q
-17.16%
IPO
-41.31%
Name
SugenTech Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sugentech Inc., a South Korean firm, develops and markets advanced in-vitro diagnostic (IVD) systems and products worldwide. Their solutions integrate biotechnology, information technology, and nanotechnology. The company's diverse portfolio features sophisticated Multiplex BLOT disease diagnostic platforms, including automated immunoblot processors and molecular diagnostic tools, alongside various test kits. They also offer a range of convenient self-testing products, such as digital ovulation, pregnancy, and early pregnancy detection kits, as well as mobile testing options. Additionally, Sugentech provides point-of-care (POC) analyzers and tests for a broad spectrum of conditions, from infectious diseases like M.tuberculosis, M.bovis, SARS-CoV-2 (antibodies and antigens), and influenza A/B, to critical biomarkers such as CRP/hsCRP/dualCRP, procalcitonin, troponin I, hemoglobinA1c, and human chorionic gonadotropin. Founded in 2011, the company, originally named Accugen Healthcare, Inc., adopted its current name, Sugentech Inc., in October 2013 and is headquartered in Daejeon.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||